(R)-tert-butyl 3-((S)-4-benzyl-2-oxooxazolidine-3-carbonyl)-5-methylhexanoate | 144287-83-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (R)-tert-butyl 3-((S)-4-benzyl-2-oxooxazolidine-3-carbonyl)-5-methylhexanoate
• 英文别名: tert-butyl (R)-3-((S)-4-benzyl-2-oxooxazolidine-3-carbonyl)-5-methylhexanoate；tert-butyl (3R)-3-[(4S)-4-benzyl-2-oxo-1,3-oxazolidine-3-carbonyl]-5-methylhexanoate
• CAS: 144287-83-2
• 化学式: C₂₂H₃₁NO₅
• 分子量: 389.492
• InChiKey: ICSNRBYEDVSHTM-MSOLQXFVSA-N

物化性质

• 沸点：
  519.8±33.0 °C(Predicted)
• 密度：
  1.124±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  28
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  72.9
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (R)-tert-butyl 3-((S)-4-benzyl-2-oxooxazolidine-3-carbonyl)-5-methylhexanoate 在 lithium hydroxide 、 双氧水 、 三乙胺 、 N,N'-羰基二咪唑 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 5.5h， 生成 (R)-3-[(S)-2-(1H-Indol-3-yl)-1-methylcarbamoyl-ethylcarbamoyl]-5-methyl-hexanoic acid
  参考文献：
  名称：

  Matrix Metalloproteinase Inhibitors:  A Structure−Activity Study

  摘要：

  Modifications around the dipeptide-mimetic core of a hydroxamic acid based matrix metalloproteinase inhibitor were studied. These variations incorporated a variety of natural, unnatural, and synthetic amino acids in addition to modifications of the P1' and P3' substituents. The results of this study indicate the following structural requirements: (1) Two key hydrogen bonds must be present between the enzyme and potent substrates. (2) Potent inhibitors must possess strong zinc-binding functionalities. (3) The potential importance of the hydrophobic group at position R3 as illustrated by its ability to impart greater relative potency against stromelysin when larger hydrophobic groups are used. (4) Requirements surrounding the nature of the amino acid appear to be more restrictive for stromelysin than for neutrophil collagenase, 72 kDa gelatinase, and 92 kDa gelatinase. These requirements may involve planar fused-ring aryl systems and possibly hydrogen-bonding capabilities.

  DOI：

  10.1021/jm970494j
• 作为产物：
  描述：

  4-甲基戊酸 在 正丁基锂 、 sodium hexamethyldisilazane 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 2.58h， 生成 (R)-tert-butyl 3-((S)-4-benzyl-2-oxooxazolidine-3-carbonyl)-5-methylhexanoate
  参考文献：
  名称：

  N-Thiazolylamide-based free fatty-acid 2 receptor agonists: Discovery, lead optimization and demonstration of off-target effect in a diabetes model

  摘要：

  Free fatty acid-2 (FFA2) receptor is a G-protein coupled receptor of interest in the development of therapeutics in metabolic and inflammatory disease areas. The discovery and optimization of an N-thiazolylamide carboxylic acid FFA2 agonist scaffold is described. Dual key objectives were to i) evaluate the potential of this scaffold for lead optimization in particular with respect to safety de-risking physicochemical properties, i.e. lipophilicity and aromatic content, and ii) to demonstrate the utility of selected lead analogues from this scaffold in a pertinent in vivo model such as oral glucose tolerance test (OGTT). As such, a concomitant improvement in bioactivity together with lipophilic ligand efficiency (LLE) and fraction sp3 content (Fsp(3)) parameters guided these efforts. Compound 10 was advanced into studies in mice on the basis of its optimized profile vs initial lead 1 (Delta LLE = 0.3, Delta Fsp(3) = 0.24). Although active in OGTT, 10 also displayed similar activity in the FFA2-knockout mice. Given this off-target OGTT effect, we discontinued development of this FFA2 agonist scaffold.

  DOI：

  10.1016/j.bmc.2018.09.015

文献信息

• Design, Synthesis, and Evaluation of Matrix Metalloprotease Inhibitors Bearing Cyclopropane-Derived Peptidomimetics as P1‘ and P2‘ Replacements
  作者：Andreas Reichelt、Christoph Gaul、Robin R. Frey、April Kennedy、Stephen F. Martin

  DOI：10.1021/jo0110698

  日期：2002.6.1

  hydrogen bonding capability associated with the P1'-P2' amide group. On the other hand, compounds 10 and 11, which contain a P2'-P3' retro amide group, were modest competitive inhibitors of a series of MMPs. The results obtained for 10 and 11 suggest that there may be a loss of hydrogen bonding capability associated with introducing the P2'-P3' retro amide group. However, because the conformationally constrained

  我们先前已经使用三取代的环丙烷作为肽替代物，以在许多重要酶的已知假肽抑制剂中诱导构象限制。环丙烷衍生的肽模拟物是新颖的，因为它们是少数以预定方式局部定向肽主链和氨基酸侧链的替代物。尽管已使用这些二肽等排体来模拟模仿chi（1）空间的gauche（-）构象的氨基酸侧链，但尚未评估它们将侧链投射为反方向的能力。作为朝着这个目标迈出的第一步，制备了构象受限的假肽8和10以及它们相应的柔性类似物9和11并作为基质金属蛋白酶（MMP）的抑制剂进行了测试。这些化合物是4和5的类似物 已知是有效的MMP抑制剂。相对于环丙烷上的肽主链取代基，预测8中的异丙基侧链和10中的芳环的反方向对应于5的P1'和P2'侧链与MMP结合时的已知方向。因此，明确设计了8和10，以探测MMP的S1'或S2'结合口袋的拓扑特征。他们还被设计来探索P1'-P2'酰胺基的重要性，该基团已知在几种MMP抑制剂复合物中形成高度保守的
• Tetrazolylpropionamides as inhibitors of Abeta protein production
  申请人：——

  公开号：US20040082568A1

  公开（公告）日：2004-04-29

  This invention relates to novel tetrazolylpropionamides in which the amide group comprises an aminoazepinone, and related structures, of Formula (I): 1 or pharmaceutically acceptable salt or prodrug forms thereof, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A&bgr;-peptide, thereby resulting in prevention and treatment of the neuropathology associated with production of A&bgr;-peptide. More particularly, the present invention relates to the treatment of neurological disorders related to &bgr;-amyloid production such as Alzheimer's disease.

  这项发明涉及新型四唑基丙酰胺，其中酰胺基团包括氨基环庚酮，以及与之相关的结构，化学式（I）： 1 或其药学上可接受的盐或前药形式，它们的药物组合物和使用方法。这些新型化合物抑制淀粉样前体蛋白的加工，更具体地说，抑制Aβ-肽的产生，从而预防和治疗与Aβ-肽产生相关的神经病理学。更具体地，本发明涉及与β-淀粉样蛋白产生相关的神经系统疾病的治疗，如阿尔茨海默病。
• [EN] CALPAIN MODULATORS AND METHODS OF PRODUCTION AND USE THEREOF<br/>[FR] MODULATEURS DE CALPAÏNE ET LEURS MÉTHODES DE PRODUCTION ET D'UTILISATION
  申请人：BLADE THERAPEUTICS INC

  公开号：WO2017156074A1

  公开（公告）日：2017-09-14

  The present technology relates to compounds, kits, compositions, and methods useful for the treatment of fibrotic disease. In some aspects, the present technology provides for treatment of various diseases or disorders associated or mediated, at least in part, by calpains, such as CAPN1, CAPN2, and/or CAPN9. The present technology is generally applicable to compounds which inhibit myofibroblast differentiation.

  这项技术涉及到用于治疗纤维化疾病的化合物、试剂盒、组合物和方法。在某些方面，这项技术提供了治疗与卡尔帕因（如CAPN1、CAPN2和/或CAPN9）至少部分相关或介导的各种疾病或疾病的方法。这项技术通常适用于抑制肌成纤维细胞分化的化合物。
• A peptide hydroxamate library for enrichment of metalloproteinases: towards an affinity-based metalloproteinase profiling protocol
  作者：Paul Geurink、Theo Klein、Michiel Leeuwenburgh、Gijs van der Marel、Henk Kauffman、Rainer Bischoff、Herman Overkleeft

  DOI：10.1039/b718352f

  日期：——

  A compound library of 96 enantiopure N-terminal succinyl hydroxamate functionalized peptides was synthesized on solid phase. All compounds were tested for their inhibitory potential towards MMP-9, MMP-12 and ADAM-17, which led to the identification of both broad spectrum inhibitors and metalloproteinase-selective ones. Eight potent and less potent inhibitors were immobilized on Sepharose beads and evaluated in solid-phase enrichment of active MMP-9, MMP-12 and ADAM-17. In addition, one of these inhibitors was used for solid-phase enrichment of endogenous ADAM-17 from a complex proteome (a lysate prepared from cultured A549 cells).

  在固相上合成了一个由 96 个对映体纯 N 端琥珀酰羟酰胺官能化肽组成的化合物库。测试了所有化合物对 MMP-9、MMP-12 和 ADAM-17 的抑制潜力，从而确定了广谱抑制剂和金属蛋白酶选择性抑制剂。在固相富集活性 MMP-9、MMP-12 和 ADAM-17 的过程中，对固定在 Sepharose 珠上的八种强效和弱效抑制剂进行了评估。此外，其中一种抑制剂还被用于固相富集复杂蛋白质组（由培养的 A549 细胞制备的裂解物）中的内源性 ADAM-17。
• A Convenient Method for the Conversion of <i>N</i>-Acyloxazolidinones to Hydroxamic Acids
  作者：Mukund P. Sibi、Hikaru Hasegawa、Sandeep R. Ghorpade

  DOI：10.1021/ol0263301

  日期：2002.10.1

  Treatment of N-acyloxazolidinones with hydroxylamines using samarium triflate as a Lewis acid provides the corresponding hydroxamic acids in 50-98% yields at room temperature. The conversion proceeds with high degree of chemoselectivity and without racemization of chiral centers alpha- to the acyl group. [reaction: see text]

  使用三氟甲磺酸sa作为路易斯酸，用羟胺处理N-酰基恶唑烷酮，在室温下以50-98％的收率提供相应的异羟肟酸。转化以高度的化学选择性进行，并且手性中心不外消旋地从α到酰基。[反应：看文字]